All Outputs (2)

Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma (2018)
Journal Article
Rogers, H. A., Chapman, R., Kings, H., Allard, J., Barron-Hastings, J., Pajtler, K. W., …Grundy, R. G. (2018). Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. Oncotarget, 9(92), 36530-36541. https://doi.org/10.18632/oncotarget.26370

Background: Epigenetic modifications have been shown to play an important role in the classification and pathogenesis of the pediatric brain tumor ependymoma, suggesting they are a potential therapeutic target. Results: Agents targeting epigenetic... Read More about Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma.

Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas (2018)
Journal Article
Pajtler, K. W., Wen, J., Sill, M., Lin, T., Orisme, W., Tang, B., …Ellison, D. W. (2018). Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 136(2), 211-226. https://doi.org/10.1007/s00401-018-1877-0

Of nine ependymoma molecular groups detected by DNA methylation profiling, the posterior fossa type A (PFA) is most prevalent. We used DNA methylation profiling to look for further molecular heterogeneity among 675 PFA ependymomas. Two major subgroup... Read More about Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.